• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diseases . SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma

tetano

Editor, Senior Moderator
Diseases


. 2023 Aug 30;11(3):112.
doi: 10.3390/diseases11030112. Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma

Pornpitra Pratedrat[SUP] 1 2 [/SUP], Duangnapa Intharasongkroh[SUP] 3 [/SUP], Jira Chansaenroj[SUP] 1 [/SUP], Preeyaporn Vichaiwattana[SUP] 1 [/SUP], Donchida Srimuan[SUP] 1 [/SUP], Thaksaporn Thatsanatorn[SUP] 1 [/SUP], Sirapa Klinfueng[SUP] 1 [/SUP], Pornjarim Nilyanimit[SUP] 1 [/SUP], Chintana Chirathaworn[SUP] 4 [/SUP], Pawinee Kupatawintu[SUP] 3 [/SUP], Dootchai Chaiwanichsiri[SUP] 3 [/SUP], Nasamon Wanlapakorn[SUP] 1 [/SUP], Yong Poovorawan[SUP] 1 5 [/SUP]



Affiliations
Abstract

Coronavirus disease 2019 (COVID-19) is a contagious illness worldwide. While guidelines for the treatment of COVID-19 have been established, the understanding of the relationship among neutralizing antibodies, cytokines, and the combined use of antiviral medications, steroid drugs, and convalescent plasma therapy remains limited. Here, we investigated the connection between the immunological response and the efficacy of convalescent plasma therapy in COVID-19 patients with moderate-to-severe pneumonia. The study included a retrospective analysis of 49 patients aged 35 to 57. We conducted clinical assessments to determine antibody levels, biochemical markers, and cytokine levels. Among the patients, 48 (98%) were discharged, while one died. We observed significantly higher levels of anti-nucleocapsid, anti-spike, and neutralizing antibodies on days 3, 7, and 14 after the transfusion compared to before treatment. Serum CRP and D-dimer levels varied significantly across these four time points. Moreover, convalescent plasma therapy demonstrated an immunoregulatory effect on cytokine parameters, with significant differences in IFN-β, IL-6, IL-10, and IFN-α levels observed at different sampling times. Evaluating the cytokine signature, along with standard clinical and laboratory parameters, may help to identify the onset of a cytokine storm in COVID-19 patients and determine the appropriate indication for anti-cytokine treatment.

Keywords: COVID-19; antibodies; convalescent plasma treatment; cytokine; retrospective study

 
Back
Top Bottom